HOUSTON ― Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL) disease. The study was published...
Tag: <span>kidney cancer</span>
Post
Targeted drug shows activity against brain metastases in kidney cancer
by Dana-Farber Cancer Institute A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need. The drug, cabozantinib, is a tyrosine kinase inhibitor that attacks several targets in cancer cells....
Post
New use of old drug reduces risk of kidney cancer returning
by European Association of Urology Credit: CC0 Public Domain Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research. The findings from the Phase III trial are presented today at the European Association of Urology Congress (EAU21). There...
Post
Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
by Beth Israel Deaconess Medical Center Credit: Pixabay/CC0 Public Domain Renal cell carcinoma (RCC) is the most common form of kidney cancer. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent....
Post
Biomarker test highly accurate in detecting early kidney cancer
by Dana-Farber Cancer Institute A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute. The report in Nature Medicine suggests that if validated in larger trials and applied widely, the non-invasive...
Post
Researchers uncover new vulnerability in kidney cancer
by Deborah Wormser, UT Southwestern Medical Center A UT Southwestern researcher led a team that identified a new vulnerability in kidney tumors, the 10th most common cause of cancer death in men and women. In their investigation of the most common type of kidney cancer, called clear cell renal cell carcinoma (ccRCC), Qing Zhang, Ph.D.,...
Post
Home urine test for prostate cancer could revolutionize diagnosis
UNIVERSITY OF EAST ANGLIA A simple urine test under development for prostate cancer detection can now use urine samples collected at home – according to new research from University of East Anglia and the Norfolk and Norwich University Hospital. Scientists pioneered the test which diagnoses aggressive prostate cancer and predicts whether patients will require treatment...
Post
Infant with deadly leukemia saved by drug for adult liver cancer
by University of California, San Francisco UCSF Benioff Children’s Hospitals have successfully treated a months-old infant with a rare childhood leukemia using a targeted therapy approved for adults with inoperable liver cancer and advanced kidney cancer. The decision to use the drug, sorafenib, was made after pathologists identified a unique mutation in the form of...
Post
Kidney disease triggers cognitive impairment, even in early stages
ERA-EDTA The link between brain dysfunction and advanced kidney disease was first noted in 1930, so it is not a new finding. Experts spoke of ‘dialysis dementia’ or ‘uremic encephalopathy’. What is new, however, is the finding that mild cognitive impairment (MCI) may already be present in earlier stages of CKD, affecting approximately one in two CKD patients (prevalence varies in studies between...
Post
MD Anderson study may explain why Immunotherapy not effective for some patients with metastatic melanoma and kidney cancer
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint blockade (ICB) therapy, according to a study at The University of Texas MD Anderson Cancer Center. Study results will be presented April 2 at...